Anika Therapeutics sees FY26 revenue $114M-$122.5M

Anika is providing the following 2026 guidance: Total Company Revenue between $114 and $122.5 million, up 1% to 9% year over year; Commercial Channel, $53 to $58 million, maintaining up 10% to 20% year over year; OEM Channel, $61 to $64.5 million, maintaining flat to modestly lower year over year; Adjusted EBITDA as a percent of revenue to 5% to 10%, reflecting higher revenues and reduced expenses offset by modestly lower U.S. pricing dynamics.